Refile: Eton Pharmaceuticals Q2 adjusted EPS beats estimates, revenue up 99% on HEMANGEOL relaunch

Eton Pharmaceuticals

13/08/2026 21:19

Corrects to reposition last Overview bullet

Overview
U.S. rare disease drugmaker's Q2 revenue rose 99% yr/yr, driven by HEMANGEOL relaunch
Adjusted EPS for Q2 beat analyst expectations
Company raised full-year 2026 revenue guidance to over $145 mln
Shares of the company were up about 24% in extended trading

Outlook
Eton raises 2026 revenue guidance to exceed $145 mln, up from more than $120 mln
Company now expects at least a 35% adjusted EBITDA margin for 2026, up from at least 30%
Eton expects full-year 2026 adjusted gross margin to exceed 70%

Result Drivers
HEMANGEOL RELAUNCH - Addition of HEMANGEOL sales and faster-than-expected patient conversion drove revenue growth
PEDIATRIC ENDOCRINOLOGY GROWTH - Strong year-over-year growth in pediatric endocrinology portfolio, including new and existing products

Company press release: ID:nGNXX23YS

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Adjusted EPS
Beat
$0.43
$0.11 (4 Analysts)
Q2 EPS
 
$0.35
 
Q2 Net Income
 
$11.58 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Eton Pharmaceuticals Inc is $61.00, about 46.7% above its August 12 closing price of $41.58
The stock recently traded at 31 times the next 12-month earnings vs. a P/E of 23 three months ago

Reuters Recommended Reads
Aug 13 - CorMedix beats Q2 revenue estimates on DefenCath growth, raises FY adjusted EBITDA guidance
Aug 12 - Liquidia Q2 revenue jumps on YUTREPIA sales
Aug 13 - Ovid Therapeutics Q2 revenue beats estimates 

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)